Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF) has extended the timetable for the planned Nasdaq listing and re-domiciliation to the United States.
The company confirms that it still intends to implement the schemes — including the resulting re-domiciliation to the United States and the associated initial public offering (IPO) of Anteris Technologies Global Corp.’s (ATGC) common stock — during the current calendar year.
Anteris advises that the scheme meetings and EGM on October 4, 2024, have been deferred to accommodate changes to the timetable, with a revised date for the meetings expected in October or November.
The company’s board of directors maintains the advantages of the Re-domiciliation significantly outweigh any disadvantages and risks. Accordingly, they continue unanimously to recommend shareholders vote in favour of the share scheme.
Anteris Technologies
Founded in Australia, Anteris is a structural heart company committed to designing, developing, and commercialising innovative medical devices. The company has a significant presence in the MedTech hub of Minneapolis, USA.
Anteris intends to revolutionise the structural heart market by delivering clinically superior solutions for significant unmet clinical needs. The company has an experienced team of multidisciplinary professionals, delivering transformative solutions to structural heart disease patients. Its lead product, DurAVR®, is a transcatheter heart valve (THV) for treating aortic stenosis.
DurAVR® THV was designed in partnership with the world’s leading interventional cardiologists and cardiac surgeons. It is the first transcatheter aortic valve replacement (TAVR) to use a single piece of bioengineered tissue. This biomimetic valve is uniquely shaped to mimic the performance of a healthy human aortic valve.